Physician profile
John Phillips
NPI 1942220637
$10,702.05
in general payments reported to CMS, 2019-2025
28 companies · $1,999 in 2025
The $1,999 reported for 2025 was more than what 76% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $787 · 2020: $726 · 2021: $1,547 · 2022: $1,824 · 2023: $1,746 · 2024: $2,073 · 2025: $1,999.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,641 · Education: $177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,640.79 |
| Education | $177.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,822.41 | 2019-2025 | |
| Genzyme Corporation | $1,007.20 | 2019-2025 | |
| Lilly USA, LLC | $925.87 | 2019-2025 | Taltz, Ebglyss |
| Ucb, INC. | $869.23 | 2019-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $810.83 | 2019-2025 | Dupixent |
| Janssen Biotech, INC. | $743.23 | 2020-2025 | Tremfya, Stelara, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $634.64 | 2019-2025 | |
| Amgen INC. | $515.04 | 2020-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $507.81 | 2019-2025 | Ilumya, Blu-U |
| Pfizer INC. | $507.52 | 2019-2025 | |
| Leo Pharma INC. | $333.88 | 2019-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $302.58 | 2022-2025 | Sotyktu |
| Sanofi-Aventis U.S. LLC | $179.98 | 2021-2024 | |
| Arcutis Biotherapeutics, INC. | $100.47 | 2023-2025 | Zoryve |
| Incyte Corporation | $55.90 | 2021-2023 | Opzelura |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $55.07 | 2022-2024 | Vtama |
| Galderma Laboratories, L.P. | $48.98 | 2021-2025 | Nemluvio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $40.20 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.46 | 2023-2024 | Spevigo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.10 | 2019 | |
| Merck Sharp & Dohme LLC | $25.71 | 2019 | |
| Organon LLC | $24.88 | 2025 | Vtama |
| Genentech USA, INC. | $24.41 | 2024 | Xolair |
| Journey Medical Corporation | $21.03 | 2023 | |
| Almirall LLC | $20.68 | 2023 | Seysara |
| Krystal Biotech INC | $18.89 | 2024 | Vyjuvek |
| Allergan, INC. | $18.46 | 2022 | |
| Janssen Scientific Affairs, LLC | $15.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.